Here's an article from Future Pundent in 2006:Cure For

New Post Public Reply Private Reply Replies (1) Message Board
L vus

Here's an article from Future Pundent in 2006: Cure For Cancer Worth $50 Trillion Just To Americans

The economic pay-off of medical research will be enormous when cures for cancer are developed. A couple of academic researchers claim that  a cure for cancer would have an economic value of $50 trillion for Americans alone . Add in the value of the cure to other industrialized societies that the total value of the cure likely exceeds $100 trillion.

A new study, to be published in a forthcoming issue of the Journal of Political Economy, calculates the prospective gains that could be obtained from further progress against major diseases. Kevin M. Murphy and Robert H. Topel, two University of Chicago researchers, estimate that even modest advancements against major diseases would have a significant impact – a 1 percent reduction in mortality from cancer has a value to Americans of nearly $500 billion. A cure for cancer would be worth about $50 trillion.

"We distinguish two types of health improvements – those that extend life and those that raise the quality of life," explain the authors. "As the population grows, as incomes grow, and as the baby-boom generation approaches the primary ages of disease-related death, the social value of improvements in health will continue to rise."

Many critiques of rising medical expenditures focus on life-extending procedures for persons near death. By breaking down net gains by age and gender, Murphy and Topel show that the value of increased longevity far exceeds rising medical expenditures overall. Gains in life expectancy over the last century were worth about $1.2 million per person to the current population, with the largest gains at birth and young age.

"An analysis of the value of health improvements is a first step toward evaluating the social returns to medical research and health-augmenting innovations," write the authors. "Improvements in life expectancy raise willingness to pay for further health improvements by increasing the value of remaining life."

Murphy and Topel also chart individual values resulting from the permanent reduction in mortality in several major diseases – including heart disease, cancer, and diabetes. Overall, reductions in mortality from 1970 to 2000 had an economic value to the U.S. population of $3.2 trillion per year.

In 2005 the US economy produced  $12.4 trillon worth of goods and services. So the value of a cancer cure equals over 4 years of US economic output.

The enormous economic value of curative treatments for cancer and similar magnitude economic value for cures for other major killers such as stroke and heart disease mean we can get huge the future returns on investment in public spending for basic biomedical research. This means increased biomedical research funding by governments is pretty easy to justify when viewed in economic terms. Yet in order to fund a war, pork, and other wastes  the Bush Administration has sought to cut biomedical research spending in inflation-adjusted terms and even  proposed a freeze in nominal dollar terms (which means that real research spending goes down by the rate at which inflation goes up).

The numbers bandied about above understate the coming return on decades of basic biomedical research. Rejuvenation therapies will lengthen working careers and brain rejuvenation will boost productivity for most years worked. Minds which have both youthful vigor and the knowledge and skills accumulated from decades of work will achieve much greater feats and operate at much higher levels of productivity.

Because the rate of advance of research can not be forecasted accurately I think there's a tendency on the part of policy makers and the public to underestimate the future return on biomedical research and in other forms of research as well. Our accumulating body of knowledge is going to reach a critical mass at some point in the next 50 years where the vast majority of diseases become curable and replacement or rejuvenation of worn aged body parts becomes commonplace. We ought try much harder to make that day come sooner.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rosti Group Expands with Alvi Acquisition

Updated Category News Views 139

Rosti Bets on Expansion with Alvi Buyout Rosti Group just rolled the dice big by swallowing Alvi Group, marking another bold move in the ever-swinging industrial and medical device manufacturing rodeo. Suddenly, we’re talking about a company with roughly 3,000 employees on its roster and a neat EUR 450 million in combined revenue. Don't overlook the power play...

Continue Reading
Credit Union Teams Up for Holiday Toy Drive in San Diego

Updated Category News Views 0

San Diego's Seasonal Giving: A Community Effort Hold onto your hats, folks—it's that time of the year when giving isn't just a suggestion; it's a full-fledged community rallying cry. Heading into the joyful chaos is North Island Credit Union, teaming up with Boys & Girls Clubs of Greater San Diego to bring the spirit of the season to children across the region. Through...

Continue Reading
NextVision's Q3 2026: Impressive Growth and Expansion

Updated Category News Views 98

NextVision's financials this quarter are the envy of tech growth companies everywhere. Their Q3 2026 report reads like a thrilling playbook for success. No half-measures here—NextVision has doubled its revenue, slashed costs, and cooked up an operating margin fit for a kingpin. Pushing Revenue to New Heights NextVision didn’t just surpass last year's revenue; it...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 164

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Expedera Teams Up with Cadence for Edge AI Supercharge

Updated Category News Views 57

A New Power Couple in AI Expedera and Cadence have decided to stir up the edge AI waters with their latest collaboration. By linking Expedera's Origin™ Evolution NPU with Cadence's Tensilica NeuroEdge 130 AI Co-Processor, we're looking at a partnership that's hell-bent on redefining efficiency and performance in edge AI systems. Breaking Down the Collaboration This...

Continue Reading
Onodrim Raises $300M to Propel EU Defence Future

Updated Category News Views 119

Onodrim Industries' Bold Bid to Reshape European Security Right out of the gate, Onodrim Industries is thundering onto the scene with a hefty $300 million Series A round to flex its muscles across Europe's defence and industrial sectors. This ain't your run-of-the-mill startup story. This is about flexing hard-earned capital to snap up established players and inject a...

Continue Reading
Bybit Expands On-Chain Access: Japanese Equity Focus

Updated Category News Views 71

Bybit's Bold Foray Into Japanese Equities Isn't every trader just itching to talk about Japan these days? Well, Bybit's got your back with its latest maneuvers. The platform is broadening its scope by diving headfirst into Japanese equities with a fresh offering—JPE backed by JX, no less. Bybit's RWA Earn platform isn't sticking to the boring fixed-income strategy...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 109

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Biond's BND-67 Trial: New Hope Against Tumors

Updated Category News Views 55

Turning Heads with a New Approach in Immunotherapy Right off the bat, let's say something's brewing in the world of cancer treatment, and it's got a promising name: BND-67. We're talking about Biond Biologics, an ambitious Israeli outfit aiming to rewrite the rules with their new kid on the block in immunotherapies. This isn't about business as usual. It's about a fresh...

Continue Reading
Foundayo Aims to Revolutionize Sleep Apnea Treatment

Updated Category News Views 81

Revolution in Sleep Health The paper has officially announced a promising shift in sleep apnea treatment. Eli Lilly's Foundayo, revealed through a Phase 3 clinical program, is looking to tackle obstructive sleep apnea (OSA) with unprecedented potential. Forget the traditional methods—this small molecule GLP-1 receptor agonist could be a game changer for folks plagued by...

Continue Reading

Top 5 Most Recently Viewed Articles

Sulliden Mining Capital's Annual Meeting Results Unveiled

Updated Category News Views 159

Sulliden Mining Capital's Annual Meeting Results Unveiled On June 30, 2025, Sulliden Mining Capital Inc. (TSX: SMC) held its Annual and Special Meeting of Shareholders. This event followed the guidelines established by the Toronto Stock Exchange. During the meeting, shareholders engaged in an essential process—electing nominees presented in the management information...

Continue Reading
Ascential Medical's Dynamic Leadership Changes for Growth

Updated Category News Views 348

Leadership Changes at Ascential Medical & Life Sciences Ellen Scipta and Chris Cowen are stepping into pivotal roles as CFO and CCO at Ascential Medical & Life Sciences, while Todd Martensen transitions to the role of CSO. These changes reflect the company's commitment to innovation and strategic growth. Introducing Ellen Scipta: New Chief Financial Officer Ellen Scipta...

Continue Reading
Investors Target Xerox Holdings for Securities Class Action

Updated Category News Views 201

Legal Investigation of Xerox Holdings Corporation Faruqi & Faruqi, LLP, a highly regarded national securities law firm, is currently investigating potential claims involving Xerox Holdings Corporation (NASDAQ: XRX). Investors who have suffered significant financial losses are encouraged to reach out to discuss options available to them. Investor Losses and Legal Options...

Continue Reading
Understanding the Risks of Sharing Back-to-School Photos

Updated Category News Views 240

Understanding the Risks of Sharing Back-to-School Photos As families across the nation prepare for a new school year, there’s an important reminder from experienced investigator and child advocate, Moses Castillo. Before sharing those back-to-school photos on social media, it's crucial to consider the potential dangers associated with such posts. The Hidden Dangers of...

Continue Reading
Intel's Journey: Overcoming Two Decades of Market Struggles

Updated Category News Views 111

Intel's Long Road to Recovery Intel has faced significant challenges over the past two decades. Its stock performance has been lackluster, rising only 2% compared to the NASDAQ 100, which has surged over 1,200%. This stark contrast raises questions about Intel's strategic decisions and future direction. Intel's leadership has stumbled in crucial areas that have allowed...

Continue Reading